Xarelto®(rivaroxaban) – New indications, new formulation approval
On December 20, 2021, the FDA approved Janssen’s Xarelto (rivaroxaban), for
- Treatment of venous thromboembolism (VTE) and the reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment; and
- Thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who have undergone the Fontan procedure
Top